Persistent COVID-19 symptoms in a community study of 606,434 people in England

Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n  ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications Jg. 13; H. 1; S. 1957 - 10
Hauptverfasser: Whitaker, Matthew, Elliott, Joshua, Chadeau-Hyam, Marc, Riley, Steven, Darzi, Ara, Cooke, Graham, Ward, Helen, Elliott, Paul
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 12.04.2022
Nature Publishing Group
Nature Portfolio
Schlagworte:
ISSN:2041-1723, 2041-1723
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n   =  97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services. This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in spring 2021) of people reported at least one symptom 12 weeks after symptom onset; identifies risk factors for persistent symptoms; and finds evidence of symptom clustering.
AbstractList Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study (n = 508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in spring 2021) of people reported at least one symptom 12 weeks after symptom onset; identifies risk factors for persistent symptoms; and finds evidence of symptom clustering.
This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in spring 2021) of people reported at least one symptom 12 weeks after symptom onset; identifies risk factors for persistent symptoms; and finds evidence of symptom clustering.
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n = 508,707; September 2020 - February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3-5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3-5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n   =  97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n = 508,707; September 2020 - February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3-5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3-5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n = 508,707; September 2020 - February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3-5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3-5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n   =  97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services. This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in spring 2021) of people reported at least one symptom 12 weeks after symptom onset; identifies risk factors for persistent symptoms; and finds evidence of symptom clustering.
ArticleNumber 1957
Author Elliott, Paul
Ward, Helen
Whitaker, Matthew
Chadeau-Hyam, Marc
Elliott, Joshua
Riley, Steven
Cooke, Graham
Darzi, Ara
Author_xml – sequence: 1
  givenname: Matthew
  orcidid: 0000-0003-1363-6537
  surname: Whitaker
  fullname: Whitaker, Matthew
  organization: School of Public Health, Imperial College London, MRC Centre for Environment and Health, Imperial College London
– sequence: 2
  givenname: Joshua
  surname: Elliott
  fullname: Elliott, Joshua
  organization: Imperial College Healthcare NHS Trust, Department of Infectious Disease, Imperial College London
– sequence: 3
  givenname: Marc
  orcidid: 0000-0001-8341-5436
  surname: Chadeau-Hyam
  fullname: Chadeau-Hyam, Marc
  organization: School of Public Health, Imperial College London, MRC Centre for Environment and Health, Imperial College London
– sequence: 4
  givenname: Steven
  surname: Riley
  fullname: Riley, Steven
  organization: School of Public Health, Imperial College London, MRC Centre for Global Infectious Disease Analysis, Imperial College London, Abdul Latif Jameel Institute for Disease & Emergency Analytics, Imperial College London
– sequence: 5
  givenname: Ara
  orcidid: 0000-0001-7815-7989
  surname: Darzi
  fullname: Darzi, Ara
  organization: Imperial College Healthcare NHS Trust, Institute of Global Health Innovation at Imperial College London
– sequence: 6
  givenname: Graham
  orcidid: 0000-0001-6475-5056
  surname: Cooke
  fullname: Cooke, Graham
  organization: Imperial College Healthcare NHS Trust, Department of Infectious Disease, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre
– sequence: 7
  givenname: Helen
  orcidid: 0000-0001-8238-5036
  surname: Ward
  fullname: Ward, Helen
  organization: Imperial College Healthcare NHS Trust, MRC Centre for Global Infectious Disease Analysis, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre
– sequence: 8
  givenname: Paul
  orcidid: 0000-0002-7511-5684
  surname: Elliott
  fullname: Elliott, Paul
  email: p.elliott@imperial.ac.uk
  organization: School of Public Health, Imperial College London, MRC Centre for Environment and Health, Imperial College London, Imperial College Healthcare NHS Trust, National Institute for Health Research Imperial Biomedical Research Centre, Health Data Research (HDR) UK London at Imperial College, UK Dementia Research Institute at Imperial College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35413949$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAUtFArWkr_AAcUiQsH0vp74wtStRRYqWo5AFfL69iLV4kdbAdp--txNqW0PdQXW88z43nP8woc-OANAG8QPEOQNOeJIsoXNcS4xoJhVN--AMcYUlSjBSYHD85H4DSlLSyLCNRQ-hIcEUYREVQcg-tvJiaXsvG5Wt78XH2qkajSrh9y6FPlfKUqHfp-9C7vqpTHdlcFW3HIP1BCq8GEoTMT7NJvOuXb1-DQqi6Z07v9BPz4fPl9-bW-uvmyWl5c1bpQc91gbluzbhDXWPCFgpwIixXW0CjKbCuIEloT2kAqoDJ0raDBDCHUGqZo6ekErGbdNqitHKLrVdzJoJzcF0LcSBWz052Ruml1Y4qCJZYSZZWAnFFLGl4qWrOi9XHWGsZ1b1pdRhFV90j08Y13v-Qm_JECQsbYZOb9nUAMv0eTsuxd0qYrAzFhTBJzKoRgENICffcEug1j9GVUexTFeIEmwbcPHd1b-fdtBYBngI4hpWjsPQRBOcVDzvGQJR5yHw95W0jNE5J2WWUXpq5c9zyVzNRU3vEbE__bfob1FwyUzPg
CitedBy_id crossref_primary_10_3390_jpm14010097
crossref_primary_10_1001_jamahealthforum_2022_1809
crossref_primary_10_1007_s44254_023_00004_8
crossref_primary_10_1093_eurpub_ckad152
crossref_primary_10_1001_jamanetworkopen_2022_40985
crossref_primary_10_1093_cid_ciae632
crossref_primary_10_1111_joim_13587
crossref_primary_10_1016_j_cpcardiol_2023_101756
crossref_primary_10_1111_joim_13584
crossref_primary_10_3389_fresc_2025_1628490
crossref_primary_10_1038_s41598_022_24307_1
crossref_primary_10_1097_CRD_0000000000000552
crossref_primary_10_3389_fendo_2024_1325939
crossref_primary_10_3390_jcm14061835
crossref_primary_10_1071_PY24163
crossref_primary_10_1038_s41598_022_26332_6
crossref_primary_10_3390_clinpract13060139
crossref_primary_10_3390_antiox14091068
crossref_primary_10_2105_AJPH_2022_306958
crossref_primary_10_1186_s12939_023_02072_5
crossref_primary_10_1016_j_rmed_2025_108173
crossref_primary_10_1016_S0140_6736_24_01136_X
crossref_primary_10_2196_48632
crossref_primary_10_3138_jammi_2023_0010
crossref_primary_10_1038_s43856_025_00832_8
crossref_primary_10_1038_s41467_022_33415_5
crossref_primary_10_3390_jcm12237313
crossref_primary_10_1016_j_neuroimage_2024_120859
crossref_primary_10_1016_j_jadohealth_2023_01_026
crossref_primary_10_1371_journal_pone_0291173
crossref_primary_10_1016_j_bbih_2024_100857
crossref_primary_10_1038_s41593_024_01576_9
crossref_primary_10_1038_s41598_024_76472_0
crossref_primary_10_1093_ageing_afad225
crossref_primary_10_1186_s12888_025_07172_w
crossref_primary_10_1186_s42358_023_00309_z
crossref_primary_10_1186_s41687_024_00737_5
crossref_primary_10_1042_BCJ20220154
crossref_primary_10_1186_s12889_024_19510_w
crossref_primary_10_1186_s13019_024_03037_7
crossref_primary_10_1016_j_clinph_2023_01_010
crossref_primary_10_5334_gh_1334
crossref_primary_10_1016_j_socscimed_2025_118368
crossref_primary_10_3389_fimmu_2024_1433531
crossref_primary_10_1136_bmjopen_2024_089508
crossref_primary_10_2188_jea_JE20220321
crossref_primary_10_3389_ijph_2022_1605086
crossref_primary_10_1371_journal_pone_0294897
crossref_primary_10_1016_S2213_2600_23_00159_5
crossref_primary_10_1093_cid_ciac661
crossref_primary_10_1016_j_jiph_2023_01_012
crossref_primary_10_1038_s41598_025_87354_4
crossref_primary_10_15829_1728_8800_2025_4406
crossref_primary_10_1038_s41467_023_44090_5
crossref_primary_10_1136_bmj_2023_074937
crossref_primary_10_1136_military_2023_002500
crossref_primary_10_1136_oemed_2024_109621
crossref_primary_10_1093_brain_awac321
crossref_primary_10_3389_fneur_2022_1095606
crossref_primary_10_1016_j_amjmed_2024_05_016
crossref_primary_10_1038_s41540_025_00488_z
crossref_primary_10_1136_archdischild_2022_324950
crossref_primary_10_1136_bmjopen_2023_072726
crossref_primary_10_3390_jcm13020392
crossref_primary_10_1016_j_jns_2022_120487
crossref_primary_10_1093_ofid_ofad471
crossref_primary_10_1016_j_jiac_2025_102720
crossref_primary_10_1038_s43856_025_00846_2
crossref_primary_10_1093_ofid_ofad233
crossref_primary_10_3390_ijerph20085529
crossref_primary_10_1007_s00467_022_05646_7
crossref_primary_10_1097_SPC_0000000000000619
crossref_primary_10_3390_jcm12020624
crossref_primary_10_59556_japi_72_0609
crossref_primary_10_1136_bmjgh_2022_011276
crossref_primary_10_1007_s00406_024_01911_y
crossref_primary_10_1161_JAHA_122_025844
crossref_primary_10_1212_NXI_0000000000200227
crossref_primary_10_1007_s12181_024_00722_8
crossref_primary_10_1186_s12891_022_05436_0
crossref_primary_10_3390_jcm12155100
crossref_primary_10_1177_21501319241295686
crossref_primary_10_1080_09638288_2024_2382904
crossref_primary_10_1186_s43166_023_00190_0
crossref_primary_10_1016_j_medcli_2022_07_002
crossref_primary_10_3390_jcm14144918
crossref_primary_10_1038_s41598_023_45461_0
crossref_primary_10_3390_covid5060091
crossref_primary_10_1186_s10020_024_00986_6
crossref_primary_10_1038_s41380_023_01951_1
crossref_primary_10_1016_j_outlook_2024_102341
crossref_primary_10_1016_j_cyto_2025_156884
crossref_primary_10_3389_fphar_2025_1565451
crossref_primary_10_1016_j_clim_2025_110564
crossref_primary_10_1080_13607863_2024_2356874
crossref_primary_10_1186_s13063_022_06817_5
crossref_primary_10_3389_fmolb_2023_1157651
crossref_primary_10_1038_s41598_023_43615_8
crossref_primary_10_1016_j_rec_2022_08_017
crossref_primary_10_1017_S0950268823001139
crossref_primary_10_1186_s12889_023_16026_7
crossref_primary_10_3390_brainsci14060587
crossref_primary_10_1016_j_jad_2025_119814
crossref_primary_10_1136_bmjresp_2023_001907
crossref_primary_10_1038_s41467_022_31897_x
crossref_primary_10_1016_j_heliyon_2024_e38276
crossref_primary_10_1016_j_heliyon_2024_e40113
crossref_primary_10_1038_s41467_023_39193_y
crossref_primary_10_3390_v14122728
crossref_primary_10_1016_j_jclinepi_2025_111867
crossref_primary_10_1080_22221751_2023_2261559
crossref_primary_10_1093_ofid_ofad320
crossref_primary_10_1177_01410768241297833
crossref_primary_10_3390_jcm12041328
crossref_primary_10_1136_bmjopen_2023_076992
crossref_primary_10_3389_fmed_2022_975930
crossref_primary_10_1136_bmj_p932
crossref_primary_10_1136_bmjph_2024_001613
crossref_primary_10_1016_j_semarthrit_2024_152455
crossref_primary_10_1093_ije_dyad033
crossref_primary_10_1186_s43556_022_00077_0
crossref_primary_10_1038_s41467_023_41879_2
crossref_primary_10_3390_life13010097
crossref_primary_10_1016_j_expneurol_2024_114921
crossref_primary_10_1016_j_idnow_2025_105091
crossref_primary_10_3389_ijph_2024_1606739
crossref_primary_10_1093_aje_kwad095
crossref_primary_10_1016_j_ebiom_2024_105493
crossref_primary_10_1016_S0140_6736_22_01385_X
crossref_primary_10_1016_j_surge_2024_08_002
crossref_primary_10_3390_jcdd10120478
crossref_primary_10_3390_jcm12030741
crossref_primary_10_1177_01410768231168377
crossref_primary_10_1016_j_jinf_2025_106500
crossref_primary_10_1136_bmjresp_2023_002137
crossref_primary_10_1016_j_janxdis_2022_102633
crossref_primary_10_3390_cells11213411
crossref_primary_10_1080_21645515_2024_2345505
crossref_primary_10_3389_fimmu_2024_1431411
crossref_primary_10_1007_s00415_023_11752_9
crossref_primary_10_1136_bmjph_2024_001166
crossref_primary_10_3389_fimmu_2022_1070994
crossref_primary_10_1016_j_bbih_2022_100586
crossref_primary_10_1136_bmjopen_2022_067449
crossref_primary_10_3390_jcm11247314
crossref_primary_10_1177_10519815251319233
crossref_primary_10_1007_s43440_023_00519_8
crossref_primary_10_1136_ard_2022_223439
crossref_primary_10_3390_app14093930
crossref_primary_10_3201_eid3007_231723
crossref_primary_10_1016_j_jshs_2023_02_006
crossref_primary_10_1016_j_micpath_2025_107398
crossref_primary_10_3390_nu17101692
crossref_primary_10_1093_milmed_usaf283
crossref_primary_10_1111_hex_70273
crossref_primary_10_1371_journal_pone_0314892
crossref_primary_10_1007_s11739_023_03195_x
crossref_primary_10_1007_s10238_023_01057_6
crossref_primary_10_3389_fmed_2024_1459583
crossref_primary_10_1038_s41440_023_01501_w
crossref_primary_10_1136_bmjresp_2023_002111
crossref_primary_10_1186_s12879_023_08783_y
crossref_primary_10_3390_bs15040432
crossref_primary_10_3389_fmed_2025_1640475
crossref_primary_10_1038_s41467_023_42726_0
crossref_primary_10_1136_bmjopen_2023_082314
crossref_primary_10_1186_s12879_025_10729_5
crossref_primary_10_1038_s41467_022_35240_2
crossref_primary_10_1093_oxfimm_iqac006
crossref_primary_10_1001_jamainternmed_2023_0750
crossref_primary_10_3390_vaccines11030699
crossref_primary_10_1016_j_healthplace_2024_103302
crossref_primary_10_1016_j_tins_2025_01_003
crossref_primary_10_1080_1600910X_2022_2098352
crossref_primary_10_3390_jcm11216278
crossref_primary_10_3390_biomedicines10112771
crossref_primary_10_1007_s12529_024_10271_9
crossref_primary_10_1016_j_labeco_2022_102281
crossref_primary_10_1186_s12889_022_14123_7
crossref_primary_10_1002_jmv_28491
crossref_primary_10_1001_jamanetworkopen_2022_40332
crossref_primary_10_1016_j_ijosm_2024_100737
crossref_primary_10_36425_rehab121733
crossref_primary_10_1038_s41598_024_74429_x
crossref_primary_10_1371_journal_pone_0294261
crossref_primary_10_1136_bmjmed_2022_000385
crossref_primary_10_3389_fnins_2023_1249282
crossref_primary_10_1002_jmv_70237
crossref_primary_10_1093_ptj_pzae042
crossref_primary_10_1136_bmjopen_2024_086578
crossref_primary_10_1371_journal_pone_0323035
crossref_primary_10_1016_j_neuro_2024_05_003
crossref_primary_10_1016_j_clinme_2024_100237
crossref_primary_10_1016_j_immuni_2022_09_006
crossref_primary_10_1136_bmj_2022_074425
crossref_primary_10_1093_eurjpc_zwae070
crossref_primary_10_2196_48043
crossref_primary_10_1002_pmrj_13098
crossref_primary_10_1136_bmjmed_2022_000257
crossref_primary_10_1016_j_cmi_2024_12_002
crossref_primary_10_1186_s41182_024_00670_9
crossref_primary_10_1124_jpet_122_001209
crossref_primary_10_1136_bmj_2022_072117
crossref_primary_10_1007_s10072_024_07427_6
crossref_primary_10_1136_jech_2024_223491
crossref_primary_10_1093_ndt_gfad121
crossref_primary_10_23749_mdl_v113i3_13092
crossref_primary_10_3389_fimmu_2022_1070379
crossref_primary_10_1016_j_jcyt_2025_04_059
crossref_primary_10_1038_s41577_023_00904_7
crossref_primary_10_1186_s12879_025_11419_y
crossref_primary_10_1371_journal_pone_0312719
crossref_primary_10_1080_00332747_2024_2379750
crossref_primary_10_1007_s11845_022_03072_0
crossref_primary_10_1186_s12879_023_08954_x
crossref_primary_10_1183_16000617_0123_2024
crossref_primary_10_5694_mja2_52473
crossref_primary_10_1002_jmv_29928
crossref_primary_10_1136_thorax_2023_220504
crossref_primary_10_3390_ijerph192214673
crossref_primary_10_1002_VIW_20220024
crossref_primary_10_2147_JMDH_S465154
crossref_primary_10_1016_j_apmr_2022_10_001
crossref_primary_10_11150_kansenshogakuzasshi_CR2025
crossref_primary_10_1111_hex_70202
crossref_primary_10_3389_fpubh_2023_1155951
crossref_primary_10_1183_23120541_00274_2022
crossref_primary_10_1097_PHM_0000000000002686
crossref_primary_10_3390_healthcare11020218
crossref_primary_10_1136_bmjopen_2022_070637
crossref_primary_10_3390_ijerph191912011
crossref_primary_10_3390_jcm11247338
crossref_primary_10_1093_biomethods_bpae076
crossref_primary_10_1136_bmj_2022_071050
crossref_primary_10_1038_s41591_023_02525_y
crossref_primary_10_1038_s43856_023_00266_0
crossref_primary_10_1017_S0950268823001759
crossref_primary_10_1002_jmv_27878
crossref_primary_10_1016_j_archger_2024_105554
crossref_primary_10_1080_24745332_2022_2156407
crossref_primary_10_1136_bmjopen_2023_080600
crossref_primary_10_1016_j_medcle_2022_10_001
crossref_primary_10_4081_monaldi_2025_3416
crossref_primary_10_1016_j_puhe_2024_02_031
crossref_primary_10_1186_s13063_024_08187_6
crossref_primary_10_17816_EID610995
Cites_doi 10.1016/S2213-2600(21)00383-0
10.1002/jmv.26459
10.1038/s41467-021-21237-w
10.3310/themedreview_45225
10.1038/s41467-021-23935-x
10.15585/mmwr.mm7037a2
10.1007/s00408-021-00423-z
10.1038/s41598-021-95565-8
10.1371/journal.pmed.1003777
10.1016/j.socscimed.2020.113426
10.1016/S0140-6736(21)02444-2
10.12688/wellcomeopenres.16228.1
10.1101/2021.02.26.21252512
10.1038/s41591-021-01433-3
10.1101/2021.03.03.21252086
10.1001/jama.2020.19719
10.3310/themedreview_41169
10.1016/j.amp.2021.02.004
10.1016/j.lanepe.2021.100098
10.1016/j.cmi.2021.02.008
10.1016/j.psychres.2020.113108
10.1136/bmjgh-2021-005427
10.1017/S0950268821000145
10.1101/2020.10.07.20208702
10.1016/j.jinf.2021.01.004
10.1080/23744235.2021.1924397
10.1093/bioinformatics/btg025
10.1038/s41591-021-01292-y
10.1001/jama.2020.12603
10.1016/j.lanepe.2021.100122
10.1126/science.abf0874
10.1016/j.csda.2006.11.025
10.1136/thoraxjnl-2020-216086
10.18637/jss.v042.i10
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-022-29521-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Computer Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database (ProQuest)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database


MEDLINE
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database (ProQuest)
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 10
ExternalDocumentID oai_doaj_org_article_c8dc8eba0f3f43afa90654f3860f3cc5
PMC9005552
35413949
10_1038_s41467_022_29521_z
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GeographicLocations England
United Kingdom--UK
GeographicLocations_xml – name: England
– name: United Kingdom--UK
GrantInformation_xml – fundername: DH | National Institute for Health Research (NIHR)
  grantid: MR/V030841/1
  funderid: https://doi.org/10.13039/501100000272
– fundername: Department of Health
– fundername: Wellcome Trust
– fundername: Wellcome Trust
  grantid: 200187/Z/15/Z
– fundername: Medical Research Council
  grantid: MR/S019669/1
– fundername: Wellcome Trust
  grantid: 200861/Z/16/Z
– fundername: Medical Research Council
  grantid: MR/R015600/1
– fundername: Medical Research Council
  grantid: MR/L01341X/1
– fundername: Medical Research Council
  grantid: MC_PC_19012
– fundername: Medical Research Council
  grantid: MC_PC_17114
– fundername: British Heart Foundation
  grantid: RE/18/4/34215
– fundername: ;
  grantid: MR/V030841/1
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LK8
M1P
M48
M7P
M~E
NAO
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
AFFHD
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AZQEC
C1K
COVID
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c606t-826fdeb816c2967a0639f2a2c0ea45fd93a9cc3480490ae4ba0e25111de5a4723
IEDL.DBID M7P
ISICitedReferencesCount 277
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000782204100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2041-1723
IngestDate Mon Nov 10 04:26:49 EST 2025
Tue Nov 04 02:05:40 EST 2025
Fri Sep 05 13:05:30 EDT 2025
Tue Oct 07 06:50:16 EDT 2025
Mon Jul 21 06:03:36 EDT 2025
Sat Nov 29 06:29:47 EST 2025
Tue Nov 18 21:21:16 EST 2025
Fri Feb 21 02:38:38 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-826fdeb816c2967a0639f2a2c0ea45fd93a9cc3480490ae4ba0e25111de5a4723
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8238-5036
0000-0003-1363-6537
0000-0001-8341-5436
0000-0002-7511-5684
0000-0001-7815-7989
0000-0001-6475-5056
OpenAccessLink https://www.proquest.com/docview/2649422712?pq-origsite=%requestingapplication%
PMID 35413949
PQID 2649422712
PQPubID 546298
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_c8dc8eba0f3f43afa90654f3860f3cc5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9005552
proquest_miscellaneous_2649995004
proquest_journals_2649422712
pubmed_primary_35413949
crossref_primary_10_1038_s41467_022_29521_z
crossref_citationtrail_10_1038_s41467_022_29521_z
springer_journals_10_1038_s41467_022_29521_z
PublicationCentury 2000
PublicationDate 2022-04-12
PublicationDateYYYYMMDD 2022-04-12
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Cirulli, E. T. et al. Long-term COVID-19 symptoms in a large unselected population. Preprint at bioRxivhttps://doi.org/10.1101/2020.10.07.20208702 (2020).
AliASiddiquiAAArshadMSIqbalFArifTBEffects of COVID-19 pandemic and lockdown on lifestyle and mental health of students: a retrospective study from Karachi, PakistanAnn. Med. Psychol.202110.1016/j.amp.2021.02.004
Del RioCCollinsLFMalaniPLong-term health consequences of COVID-19JAMA20203241723172410.1001/jama.2020.19719
DaviesBCommunity factors and excess mortality in first wave of the COVID-19 pandemic in EnglandNat. Commun.2021122021NatCo..12.3755D1:CAS:528:DC%2BB3MXhtl2jsrzJ10.1038/s41467-021-23935-x
MichelenMCharacterising long COVID: a living systematic reviewBMJ Glob. Health20216e00542710.1136/bmjgh-2021-005427
VenturelliSSurviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluationEpidemiol. Infect.2021149e321:CAS:528:DC%2BB3MXjvV2ltL8%3D10.1017/S0950268821000145
Hennig, C. fpc: Flexible Procedures for Clustering. 2020. https://cran.r-project.org/web/packages/fpc/index.html.
Living with Covid19. https://evidence.nihr.ac.uk/themedreview/living-with-covid19/, https://doi.org/10.3310/themedreview_41169 (Accessed 31 March 2022).
ElliottJPredictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million peoplePLoS Med.202118e10037771:CAS:528:DC%2BB3MXit1eitrbP10.1371/journal.pmed.1003777
Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. https://doi.org/10.1038/s41591-021-01433-3 (2021).
Ward, H. et al. Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancethttps://doi.org/10.1016/S0140-6736(21)02444-2 (2021).
KleinHOnset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patientsClin. Microbiol. Infect.202110.1016/j.cmi.2021.02.008338131168015344
Imperial College London. Real-time Assessment of Community Transmission (REACT) study. https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/ (accessed 31 March 2022).
Huang, Y. et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. Preprint at medRxivhttps://doi.org/10.1101/2021.03.03.21252086 (2021).
Evans, R. A. et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(21)00383-0 (2021).
Sorensen & Julius, T. A Method of Establishing Groups of Equal Amplitude in Plant Sociology Based on Similarity of Species Content and Its Application to Analyses of the Vegetation on Danish Commons (I kommission hos E. Munksgaard, 1948).
CallardFPeregoEHow and why patients made Long CovidSoc. Sci. Med.202126811342610.1016/j.socscimed.2020.113426
TomasoniDAnxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, ItalyJ. Med. Virol.202193117511791:CAS:528:DC%2BB3cXhvFCrurzK10.1002/jmv.26459
Fernández-de-Las-PeñasCLong-term post-COVID symptoms and associated risk factors in previously hospitalized patients: a multicenter studyJ. Infect.202183237279339843998110627
Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep.11. https://doi.org/10.1038/s41598-021-95565-8 (2021).
HennigCCluster-wise assessment of cluster stabilityComput. Stat. Data Anal.200752258271240998010.1016/j.csda.2006.11.025
MorgülEKallitsoglouAEssauCAPsychological effects of the COVID-19 lockdown on children and families in the UKRev. Psicol. Clín. con Niños Adolesc202074228
ArnoldDTPatient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohortThorax20217639940110.1136/thoraxjnl-2020-216086
Ayoubkhani, D., Pawelek, P. & Gaughan, C. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021 (2021).
SykesDLPost-COVID-19 symptom burden: what is long-COVID and how should we manage it?Lung20211991131191:CAS:528:DC%2BB3MXktlWrtb8%3D10.1007/s00408-021-00423-z
EFS Survey. Version EFS Sprint 2020 (Questback GmbH, 2020).
AugustinMPost-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort studyLancet Reg. Health Eur.2021610012210.1016/j.lanepe.2021.100122
Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance (NICE).
Living with Covid19—Second Review. https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/, https://doi.org/10.3310/themedreview_45225 (Accessed 31 March 2022).
LinzerDALewisJBpoLCA: an R package for polytomous variable latent class analysisJ. Stat. Softw.20114212910.18637/jss.v042.i10
RileySResurgence of SARS-CoV-2: detection by community viral surveillanceScience20213729909951:CAS:528:DC%2BB3MXht1WrsL%2FP10.1126/science.abf0874
CarfìABernabeiRLandiFGemelli Against COVID-19 Post-Acute Care Study Group.Persistent symptoms in patients after acute COVID-19JAMA202032460360510.1001/jama.2020.12603
Ayoubkhani, D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021).
Odriozola-GonzálezPPlanchuelo-GómezÁIrurtiaMJde Luis-GarcíaRPsychological effects of the COVID-19 outbreak and lockdown among students and workers of a Spanish universityPsychiatry Res.202029011310810.1016/j.psychres.2020.113108
Yong, S. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases53, 737–754 (2021).
WardHSARS-CoV-2 antibody prevalence in England following the first peak of the pandemicNat. Commun.2021122021NatCo..12..905W1:CAS:528:DC%2BB3MXjvFKns7c%3D10.1038/s41467-021-21237-w
SudreCHAttributes and predictors of long COVIDNat. Med.2021276266311:CAS:528:DC%2BB3MXmt1entb0%3D10.1038/s41591-021-01292-y
Moreno-PérezOPost-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort studyJ. Infect.20218237838310.1016/j.jinf.2021.01.004
WardHPrevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adultsLancet Reg. Health Eur.2021410009810.1016/j.lanepe.2021.100098
YomogidaKPost-acute sequelae of SARS-CoV-2 infection among adults aged ≥18 years—Long Beach, California, April 1–December 10, 2020Morb. Mortal. Wkly. Rep.202170127412771:CAS:528:DC%2BB3MXitF2lsb7F10.15585/mmwr.mm7037a2
Timeline of UK government coronavirus lockdowns. https://www.instituteforgovernment.org.uk/charts/uk-government-coronavirus-lockdowns (accessed 31 March 2022).
RileySREal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: study protocolWellcome Open Res.2020520010.12688/wellcomeopenres.16228.1
Urgent need for more research to understand Long Covid. https://royalsociety.org/news/2020/10/urgent-need-to-understand-long-covid/ (Accessed 31 March 2022).
Team RC. R Core Team R: A Language and Environment For Statistical Computing (R foundation for Statistical Computing, Austria, Vienna, 2018).
Ward, H. et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. https://doi.org/10.1101/2021.02.26.21252512 (2021).
Prokhorenkova, L., Gusev, G., Vorobev, A., Dorogush, A. V. & Gulin, A. CatBoost: unbiased boosting with categorical features. Preprint at arXiv [cs.LG]: 1706.09516 (2017).
DattaSDattaSComparisons and validation of statistical clustering techniques for microarray gene expression dataBioinformatics2003194594661:CAS:528:DC%2BD3sXit1yns70%3D10.1093/bioinformatics/btg025
M Augustin (29521_CR6) 2021; 6
29521_CR23
M Michelen (29521_CR29) 2021; 6
29521_CR46
29521_CR22
29521_CR44
O Moreno-Pérez (29521_CR19) 2021; 82
29521_CR27
J Elliott (29521_CR32) 2021; 18
29521_CR47
S Riley (29521_CR30) 2021; 372
C Hennig (29521_CR42) 2007; 52
H Ward (29521_CR34) 2021; 4
C Fernández-de-Las-Peñas (29521_CR33) 2021; 83
A Ali (29521_CR24) 2021
B Davies (29521_CR36) 2021; 12
S Venturelli (29521_CR17) 2021; 149
29521_CR12
29521_CR13
29521_CR35
29521_CR10
D Tomasoni (29521_CR18) 2021; 93
C Del Rio (29521_CR2) 2020; 324
29521_CR9
H Klein (29521_CR11) 2021
29521_CR16
S Datta (29521_CR43) 2003; 19
29521_CR39
29521_CR37
29521_CR4
29521_CR3
P Odriozola-González (29521_CR26) 2020; 290
29521_CR1
K Yomogida (29521_CR21) 2021; 70
DT Arnold (29521_CR14) 2021; 76
29521_CR5
CH Sudre (29521_CR8) 2021; 27
DL Sykes (29521_CR28) 2021; 199
A Carfì (29521_CR15) 2020; 324
DA Linzer (29521_CR45) 2011; 42
S Riley (29521_CR38) 2020; 5
H Ward (29521_CR31) 2021; 12
F Callard (29521_CR7) 2021; 268
E Morgül (29521_CR25) 2020; 7
29521_CR41
29521_CR20
29521_CR40
References_xml – reference: LinzerDALewisJBpoLCA: an R package for polytomous variable latent class analysisJ. Stat. Softw.20114212910.18637/jss.v042.i10
– reference: HennigCCluster-wise assessment of cluster stabilityComput. Stat. Data Anal.200752258271240998010.1016/j.csda.2006.11.025
– reference: Living with Covid19. https://evidence.nihr.ac.uk/themedreview/living-with-covid19/, https://doi.org/10.3310/themedreview_41169 (Accessed 31 March 2022).
– reference: Huang, Y. et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. Preprint at medRxivhttps://doi.org/10.1101/2021.03.03.21252086 (2021).
– reference: Hennig, C. fpc: Flexible Procedures for Clustering. 2020. https://cran.r-project.org/web/packages/fpc/index.html.
– reference: Imperial College London. Real-time Assessment of Community Transmission (REACT) study. https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/ (accessed 31 March 2022).
– reference: Evans, R. A. et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(21)00383-0 (2021).
– reference: MichelenMCharacterising long COVID: a living systematic reviewBMJ Glob. Health20216e00542710.1136/bmjgh-2021-005427
– reference: Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance (NICE).
– reference: Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. https://doi.org/10.1038/s41591-021-01433-3 (2021).
– reference: Prokhorenkova, L., Gusev, G., Vorobev, A., Dorogush, A. V. & Gulin, A. CatBoost: unbiased boosting with categorical features. Preprint at arXiv [cs.LG]: 1706.09516 (2017).
– reference: Cirulli, E. T. et al. Long-term COVID-19 symptoms in a large unselected population. Preprint at bioRxivhttps://doi.org/10.1101/2020.10.07.20208702 (2020).
– reference: SudreCHAttributes and predictors of long COVIDNat. Med.2021276266311:CAS:528:DC%2BB3MXmt1entb0%3D10.1038/s41591-021-01292-y
– reference: Timeline of UK government coronavirus lockdowns. https://www.instituteforgovernment.org.uk/charts/uk-government-coronavirus-lockdowns (accessed 31 March 2022).
– reference: SykesDLPost-COVID-19 symptom burden: what is long-COVID and how should we manage it?Lung20211991131191:CAS:528:DC%2BB3MXktlWrtb8%3D10.1007/s00408-021-00423-z
– reference: TomasoniDAnxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, ItalyJ. Med. Virol.202193117511791:CAS:528:DC%2BB3cXhvFCrurzK10.1002/jmv.26459
– reference: ElliottJPredictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million peoplePLoS Med.202118e10037771:CAS:528:DC%2BB3MXit1eitrbP10.1371/journal.pmed.1003777
– reference: DaviesBCommunity factors and excess mortality in first wave of the COVID-19 pandemic in EnglandNat. Commun.2021122021NatCo..12.3755D1:CAS:528:DC%2BB3MXhtl2jsrzJ10.1038/s41467-021-23935-x
– reference: Sorensen & Julius, T. A Method of Establishing Groups of Equal Amplitude in Plant Sociology Based on Similarity of Species Content and Its Application to Analyses of the Vegetation on Danish Commons (I kommission hos E. Munksgaard, 1948).
– reference: EFS Survey. Version EFS Sprint 2020 (Questback GmbH, 2020).
– reference: ArnoldDTPatient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohortThorax20217639940110.1136/thoraxjnl-2020-216086
– reference: YomogidaKPost-acute sequelae of SARS-CoV-2 infection among adults aged ≥18 years—Long Beach, California, April 1–December 10, 2020Morb. Mortal. Wkly. Rep.202170127412771:CAS:528:DC%2BB3MXitF2lsb7F10.15585/mmwr.mm7037a2
– reference: Moreno-PérezOPost-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort studyJ. Infect.20218237838310.1016/j.jinf.2021.01.004
– reference: Ayoubkhani, D., Pawelek, P. & Gaughan, C. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021 (2021).
– reference: Team RC. R Core Team R: A Language and Environment For Statistical Computing (R foundation for Statistical Computing, Austria, Vienna, 2018).
– reference: Fernández-de-Las-PeñasCLong-term post-COVID symptoms and associated risk factors in previously hospitalized patients: a multicenter studyJ. Infect.202183237279339843998110627
– reference: Ward, H. et al. Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancethttps://doi.org/10.1016/S0140-6736(21)02444-2 (2021).
– reference: AugustinMPost-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort studyLancet Reg. Health Eur.2021610012210.1016/j.lanepe.2021.100122
– reference: MorgülEKallitsoglouAEssauCAPsychological effects of the COVID-19 lockdown on children and families in the UKRev. Psicol. Clín. con Niños Adolesc202074228
– reference: Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep.11. https://doi.org/10.1038/s41598-021-95565-8 (2021).
– reference: WardHPrevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adultsLancet Reg. Health Eur.2021410009810.1016/j.lanepe.2021.100098
– reference: Urgent need for more research to understand Long Covid. https://royalsociety.org/news/2020/10/urgent-need-to-understand-long-covid/ (Accessed 31 March 2022).
– reference: CallardFPeregoEHow and why patients made Long CovidSoc. Sci. Med.202126811342610.1016/j.socscimed.2020.113426
– reference: CarfìABernabeiRLandiFGemelli Against COVID-19 Post-Acute Care Study Group.Persistent symptoms in patients after acute COVID-19JAMA202032460360510.1001/jama.2020.12603
– reference: AliASiddiquiAAArshadMSIqbalFArifTBEffects of COVID-19 pandemic and lockdown on lifestyle and mental health of students: a retrospective study from Karachi, PakistanAnn. Med. Psychol.202110.1016/j.amp.2021.02.004
– reference: Ayoubkhani, D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021).
– reference: Ward, H. et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. https://doi.org/10.1101/2021.02.26.21252512 (2021).
– reference: VenturelliSSurviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluationEpidemiol. Infect.2021149e321:CAS:528:DC%2BB3MXjvV2ltL8%3D10.1017/S0950268821000145
– reference: RileySResurgence of SARS-CoV-2: detection by community viral surveillanceScience20213729909951:CAS:528:DC%2BB3MXht1WrsL%2FP10.1126/science.abf0874
– reference: WardHSARS-CoV-2 antibody prevalence in England following the first peak of the pandemicNat. Commun.2021122021NatCo..12..905W1:CAS:528:DC%2BB3MXjvFKns7c%3D10.1038/s41467-021-21237-w
– reference: Odriozola-GonzálezPPlanchuelo-GómezÁIrurtiaMJde Luis-GarcíaRPsychological effects of the COVID-19 outbreak and lockdown among students and workers of a Spanish universityPsychiatry Res.202029011310810.1016/j.psychres.2020.113108
– reference: DattaSDattaSComparisons and validation of statistical clustering techniques for microarray gene expression dataBioinformatics2003194594661:CAS:528:DC%2BD3sXit1yns70%3D10.1093/bioinformatics/btg025
– reference: Del RioCCollinsLFMalaniPLong-term health consequences of COVID-19JAMA20203241723172410.1001/jama.2020.19719
– reference: Yong, S. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases53, 737–754 (2021).
– reference: RileySREal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: study protocolWellcome Open Res.2020520010.12688/wellcomeopenres.16228.1
– reference: Living with Covid19—Second Review. https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/, https://doi.org/10.3310/themedreview_45225 (Accessed 31 March 2022).
– reference: KleinHOnset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patientsClin. Microbiol. Infect.202110.1016/j.cmi.2021.02.008338131168015344
– ident: 29521_CR16
  doi: 10.1016/S2213-2600(21)00383-0
– volume: 93
  start-page: 1175
  year: 2021
  ident: 29521_CR18
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.26459
– volume: 12
  year: 2021
  ident: 29521_CR31
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-21237-w
– ident: 29521_CR3
  doi: 10.3310/themedreview_45225
– volume: 12
  year: 2021
  ident: 29521_CR36
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-23935-x
– volume: 70
  start-page: 1274
  year: 2021
  ident: 29521_CR21
  publication-title: Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm7037a2
– volume: 199
  start-page: 113
  year: 2021
  ident: 29521_CR28
  publication-title: Lung
  doi: 10.1007/s00408-021-00423-z
– ident: 29521_CR5
  doi: 10.1038/s41598-021-95565-8
– volume: 18
  start-page: e1003777
  year: 2021
  ident: 29521_CR32
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.1003777
– volume: 268
  start-page: 113426
  year: 2021
  ident: 29521_CR7
  publication-title: Soc. Sci. Med.
  doi: 10.1016/j.socscimed.2020.113426
– ident: 29521_CR47
– ident: 29521_CR9
– ident: 29521_CR4
– ident: 29521_CR40
– ident: 29521_CR37
  doi: 10.1016/S0140-6736(21)02444-2
– volume: 5
  start-page: 200
  year: 2020
  ident: 29521_CR38
  publication-title: Wellcome Open Res.
  doi: 10.12688/wellcomeopenres.16228.1
– ident: 29521_CR35
  doi: 10.1101/2021.02.26.21252512
– ident: 29521_CR22
  doi: 10.1038/s41591-021-01433-3
– ident: 29521_CR20
  doi: 10.1101/2021.03.03.21252086
– volume: 324
  start-page: 1723
  year: 2020
  ident: 29521_CR2
  publication-title: JAMA
  doi: 10.1001/jama.2020.19719
– ident: 29521_CR13
  doi: 10.3310/themedreview_41169
– year: 2021
  ident: 29521_CR24
  publication-title: Ann. Med. Psychol.
  doi: 10.1016/j.amp.2021.02.004
– volume: 4
  start-page: 100098
  year: 2021
  ident: 29521_CR34
  publication-title: Lancet Reg. Health Eur.
  doi: 10.1016/j.lanepe.2021.100098
– year: 2021
  ident: 29521_CR11
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2021.02.008
– volume: 290
  start-page: 113108
  year: 2020
  ident: 29521_CR26
  publication-title: Psychiatry Res.
  doi: 10.1016/j.psychres.2020.113108
– ident: 29521_CR27
– volume: 6
  start-page: e005427
  year: 2021
  ident: 29521_CR29
  publication-title: BMJ Glob. Health
  doi: 10.1136/bmjgh-2021-005427
– volume: 149
  start-page: e32
  year: 2021
  ident: 29521_CR17
  publication-title: Epidemiol. Infect.
  doi: 10.1017/S0950268821000145
– ident: 29521_CR1
– ident: 29521_CR10
  doi: 10.1101/2020.10.07.20208702
– volume: 82
  start-page: 378
  year: 2021
  ident: 29521_CR19
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2021.01.004
– ident: 29521_CR46
– ident: 29521_CR12
  doi: 10.1080/23744235.2021.1924397
– ident: 29521_CR44
– ident: 29521_CR23
– volume: 19
  start-page: 459
  year: 2003
  ident: 29521_CR43
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btg025
– volume: 27
  start-page: 626
  year: 2021
  ident: 29521_CR8
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01292-y
– ident: 29521_CR41
– volume: 7
  start-page: 42
  year: 2020
  ident: 29521_CR25
  publication-title: Rev. Psicol. Clín. con Niños Adolesc
– ident: 29521_CR39
– volume: 324
  start-page: 603
  year: 2020
  ident: 29521_CR15
  publication-title: JAMA
  doi: 10.1001/jama.2020.12603
– volume: 6
  start-page: 100122
  year: 2021
  ident: 29521_CR6
  publication-title: Lancet Reg. Health Eur.
  doi: 10.1016/j.lanepe.2021.100122
– volume: 372
  start-page: 990
  year: 2021
  ident: 29521_CR30
  publication-title: Science
  doi: 10.1126/science.abf0874
– volume: 52
  start-page: 258
  year: 2007
  ident: 29521_CR42
  publication-title: Comput. Stat. Data Anal.
  doi: 10.1016/j.csda.2006.11.025
– volume: 76
  start-page: 399
  year: 2021
  ident: 29521_CR14
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2020-216086
– volume: 83
  start-page: 237
  year: 2021
  ident: 29521_CR33
  publication-title: J. Infect.
– volume: 42
  start-page: 1
  year: 2011
  ident: 29521_CR45
  publication-title: J. Stat. Softw.
  doi: 10.18637/jss.v042.i10
SSID ssj0000391844
Score 2.7161443
Snippet Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n  ...
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n =...
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study (n =...
This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1957
SubjectTerms 631/114/2164
631/326/596/4130
692/699/255/2514
692/700/478/174
Adult
Cluster analysis
Clustering
Complications
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
Deprivation
England - epidemiology
Estimates
Female
Health care
Humanities and Social Sciences
Humans
Long COVID
Medical personnel
multidisciplinary
Post-Acute COVID-19 Syndrome
Risk analysis
Risk factors
SARS-CoV-2
Science
Science (multidisciplinary)
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dT9wwDLcmxKS9INgHFNiUSbyNijZJr_EjY0ObNB08MMRbFHKJOAl6iBak46_HSXo3bl-88No4bWo7sS07PwPsyMqTppQ-L5U3uXS2yDFgEZKxVVZYg4PYG_D0Rz0cqrMzPH7U6ivUhCV44MS4PatGVrlzU3jhpTDeYLgO6YUa0BNrI3ppUeOjYCqewQIpdJH9LZlCqL1WxjMhFK9zJJuV3y9YogjY_zcv889iyd8yptEQHa7CSu9Bsv208jV44ZrX8DL1lJy-gWGoaQ-yazp2cHT6_UteImunV9fd5Kpl44YZZtOlkG7KIrgsm3hGAcauFJKlgvJA1nf3eAs_D7-eHHzL-6YJuSXSLqdwwY_cuSoHluOgNsEF8dxwWzhDghmhMGitkCqk_IyTxFkXwoxy5Cojay7ewVIzadwGMK6c8IXnNZl0WTmvHJrKkIdFr6FJPINyxkBte0Tx0NjiUsfMtlA6MV0T03Vkur7P4NN8znXC0_gv9ecglzllwMKOD0hDdK8h-ikNyWB7JlXdb9BWkx-IkvO6pL_4OB-mrRXyJaZxk9tEg1jRMZLBelKC-UpERdYfJWZQL6jHwlIXR5rxRYTvxoB7VtF3d2eK9GtZ_2bF5nOwYgte8bADIlblNix1N7fuPSzbu27c3nyIW-gBRfcctg
  priority: 102
  providerName: Directory of Open Access Journals
Title Persistent COVID-19 symptoms in a community study of 606,434 people in England
URI https://link.springer.com/article/10.1038/s41467-022-29521-z
https://www.ncbi.nlm.nih.gov/pubmed/35413949
https://www.proquest.com/docview/2649422712
https://www.proquest.com/docview/2649995004
https://pubmed.ncbi.nlm.nih.gov/PMC9005552
https://doaj.org/article/c8dc8eba0f3f43afa90654f3860f3cc5
Volume 13
WOSCitedRecordID wos000782204100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Advanced Technologies & Aerospace Database
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: P5Z
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M7P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: 7X7
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: BENPR
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database (ProQuest)
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: PIMPY
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiQuvAuBsjISNxo1sZ2NfUK0tKISLBGCauFiuY4NK9Fk2aRI21_P2MmmWh69cMkhniR2ZsYz9oy_AXjOM4eSkro4FU7H3Joklh6LEI2tMMxoOQ61AU_e5pOJmE5l0W-4NX1a5WpODBN1WRu_R76HhltySvOUvpz_iH3VKB9d7UtobMCWR0mgIXWvGPZYPPq54Lw_K5MwsdfwMDP4FHYq0XLFF2v2KMD2_83X_DNl8re4aTBHR7f_dyB34FbviJJXneTchWu2ugc3utKUy_sw8anxXgSqlhy8Pzl-HaeSNMuzeVufNWRWEU1Md7akXZKAUUtqR3CdsssZJ11euifri4Q8gE9Hhx8P3sR97YXYIGkb46rDlfZUpGND5TjX3pNxVFOTWI38LSXT0hjGhY8castPdWL9aiUtbaZ5Ttk2bFZ1ZR8BocIylziao2fAM-uElTrT6Kjha_AhGkG64oAyPTC5r4_xXYUAOROq45pCrqnANXURwYvhmXkHy3El9b5n7EDpIbXDjXrxVfUaqowojbA4DsccZ9pp6c_dOibGeMeYLIKdFT9Vr-eNumRmBM-GZtRQH3bRla3POxopM5yNInjYSdHQE5ahEyG5jCBfk6-1rq63VLNvAQVcevi0DL-7u5LEy279-1c8vnoUT-Am9coRwCx3YLNdnNuncN38bGfNYgQb-TQPVzGCrf3DSfFhFDYxRkHv8FpkX7ClOH5XfP4Falswkw
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VWxBceD8CBYwEJxp1Yzsb-4AQtFRddbvsoVTtybheG1aiybJJQdsfxW9k7CRbLY_eeuAa28nY_jwzscffALzgqUOkJC5OhNMxt6YbS89FiMZWGGa07IXcgAeDbDgUh4dytAI_27swPqyy1YlBUY8L4_fIN9BwS05pltA302-xzxrlT1fbFBo1LHbt_Af-spWv-1s4vy8p3X6_v7kTN1kFYoPOehWjP-3G9lgkPUNlL9PeRjuqqelajZKPJdPSGMaFPxPTlh_rrvV-eDK2qeaZJzpAlb_KPdg7sDrq742OFrs6nm9dcN7czukysVHyoIt80DyVaCvjsyULGBIF_M27_TNI87eT2mAAt2_-b0N3C240rjZ5W6-N27Bi8ztwtU6-Ob8LQx_870GeV2Tzw0F_K04kKecn06o4KckkJ5qY-vZMNSeBhZcUjqCE65xxUkfe-2pNGpR78PFSOnMfOnmR24dAqLDMdR3N0PfhqXXCSp1qdEXxNdiIRpC0M65MQ73uM4B8VSEEgAlVo0QhSlRAiTqL4NWizbQmHrmw9jsPpEVNTxoeHhSzz6rRQcqIsREW--GY40w7Lf3NYsdED58Yk0aw1uJHNZqsVOfgieD5ohh1kD9Y0rktTus6UqaobyN4UKN2IQlL0U2SXEaQLeF5SdTlknzyJfCcS08Ql-J311vkn4v176F4dHEvnsG1nf29gRr0h7uP4Tr1CzNQd65Bp5qd2idwxXyvJuXsabO2CXy67DXxC5MCh3E
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaq8hAX3o9AASPBiUa7sZ2NfUAIuqxYtVr2AFXFxbiODSvRZNmkoO1P49cx4yRbLY_eeuCaOIntfPOwPfMNIU9F6gEpiY8T6U0snO3HCrkIwdhKy61Rg1AbcH8vm0zkwYGabpCfXS4MhlV2OjEo6ry0uEfeA8OtBGNZwnq-DYuYDkcv599irCCFJ61dOY0GIrtu-QOWb9WL8RD-9TPGRm_e77yN2woDsQXHvY7Bt_a5O5TJwDI1yAzaa88Ms31nYBS54kZZy4XE8zHjxKHpO_TJk9ylRmRIegDq_0IGa0wMJ5ymH1f7O8i8LoVo83T6XPYqEbQShs8zBVYzPlmzhaFkwN_83D_DNX87sw2mcHTtf57E6-Rq64DTV43E3CAbrrhJLjUlOZe3yARTAhD6RU133u2Ph3GiaLU8mtflUUVnBTXUNjk19ZIGbl5aego93BZc0CYeH5u1xVFukw_nMpg7ZLMoC3ePUCYd933PMvCIROq8dMqkBhxUeA08xCKSdH9f25aQHeuCfNUhMIBL3SBGA2J0QIw-icjz1TPzho7kzNavEVSrlkglHi6Ui8-61UzaytxKB-Pw3AtuvFGYb-y5HMAVa9OIbHVY0q1-q_QpkCLyZHUbNBMeN5nClcdNG6VS0MIRudsgeNUTnoLzpISKSLaG7bWurt8pZl8C-7lC2rgUvrvdScFpt_49FffPHsVjchkEQe-NJ7sPyBWGMhr4PLfIZr04dg_JRfu9nlWLR0HIKfl03gLxC8GWjtQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Persistent+COVID-19+symptoms+in+a+community+study+of+606%2C434+people+in+England&rft.jtitle=Nature+communications&rft.au=Whitaker%2C+Matthew&rft.au=Elliott%2C+Joshua&rft.au=Chadeau-Hyam%2C+Marc&rft.au=Riley%2C+Steven&rft.date=2022-04-12&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=13&rft.issue=1&rft.spage=1957&rft_id=info:doi/10.1038%2Fs41467-022-29521-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon